文献速递心律失常血脂与心血管预防

阿哌沙班治疗房颤的美国经济学分析:ARISTOTLE随机临床试验结果

Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2017-01-01

基于ARISTOTLE试验中3417例美国房颤患者的数据,从美国医疗系统角度评估阿哌沙班对比华法林的成本效果。随访中位1.8年,阿哌沙班组质量调整生命年显著长于华法林组(7.94 vs 7.54),增量成本为每获得1个质量调整生命年53925美元,98%概率低于10万美元意愿支付阈值。

要点

  • 阿哌沙班组质量调整生命年显著长于华法林组(7.94 vs 7.54)。
  • 增量成本效果比为每质量调整生命年53925美元,98%概率低于10万美元阈值。
  • 抗凝治疗2年后两组医疗费用(不含研究药物)无统计学差异。

核心结论

  • 对于符合ARISTOTLE入选标准的房颤患者,阿哌沙班治疗以合理的增量成本提供临床获益,按美国成本效果基准判断具有合理的经济价值。

研究设计与样本

  • 基于ARISTOTLE随机临床试验患者层面资源使用和临床数据的经济学分析,该试验为多国随机临床试验,观察18201例患者(其中美国患者3417例),中位随访1.8年,时间范围为2006年至2011年。
  • 从美国医疗系统角度进行成本效果分析,使用外部推导的美国成本权重,并进行了广泛的敏感性分析。

主要发现

  • 3417例美国患者平均(标准差)年龄为71(10)岁,男性2329例(68.2%),白人3264例(95.5%)。
  • 抗凝治疗2年后,阿哌沙班组与华法林组患者的医疗费用(不含研究药物)无统计学差异(差值,-60美元;95%CI,-2728至2608美元)。
  • 基于ARISTOTLE结局建模,阿哌沙班组预期寿命显著长于华法林组(7.94 vs 7.54质量调整生命年)。
  • 包括抗凝药物和监测成本在内的增量成本为每质量调整生命年53925美元,98%概率符合10万美元意愿支付阈值。
  • 当模型假设变化时结果总体一致,终身成本效果受阿哌沙班价格和时间跨度影响最大。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial reported that apixaban therapy was superior to warfarin therapy in preventing stroke and all-cause death while causing significantly fewer major bleeds. To establish the value proposition of substituting apixiban therapy for warfarin therapy in patients with atrial fibrillation, we performed a cost-effectiveness analysis using patient-level data from the ARISTOTLE trial. OBJECTIVE: To assess the cost and cost-effectiveness of apixaban therapy compared with warfarin therapy in patients with atrial fibrillation from the perspective of the US health care system. DESIGN, SETTING, AND PARTICIPANTS: This economic analysis uses patient-level resource use and clinical data collected in the ARISTOTLE trial, a multinational randomized clinical trial that observed 18 201 patients (3417 US patients) for a median of 1.8 years between 2006 and 2011. INTERVENTIONS: Apixaban therapy vs warfarin therapy. MAIN OUTCOMES AND MEASURES: Within-trial resource use and cost were compared between treatments, using externally derived US cost weights. Life expectancies for US patients were estimated according to their baseline risk and treatment using time-based and age-based survival models developed using the overall ARISTOTLE population. Quality-of-life adjustment factors were obtained from external sources. Cost-effectiveness (incremental cost per quality-adjusted life-year gained) was evaluated from a US perspective, and extensive sensitivity analyses were performed. RESULTS: Of the 3417 US patients enrolled in ARISTOTLE, the mean (SD) age was 71 (10) years; 2329 (68.2%) were male and 3264 (95.5%) were white. After 2 years of anticoagulation therapy, health care costs (excluding the study drug) of patients treated with apixaban therapy and warfarin therapy were not statistically different (difference, -$60; 95% CI, -$2728 to $2608). Life expectancy, modeled from ARISTOTLE outcomes, was significantly longer with apixaban therapy vs warfarin therapy (7.94 vs 7.54 quality-adjusted life years). The incremental cost, including cost of anticoagulant and monitoring, of achieving these benefits was within accepted US norms ($53 925 per quality-adjusted life year, with 98% likelihood of meeting a $100 000 willingness-to-pay threshold). Results were generally consistent when model assumptions were varied, with lifetime cost-effectiveness most affected by the price of apixaban and the time horizon. CONCLUSIONS AND RELEVANCE: Apixaban therapy for ARISTOTLE-eligible patients with atrial fibrillation provides clinical benefits at an incremental cost that represents reasonable value for money judged using US benchmarks for cost-effectiveness. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00412984.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Cowper PA, Sheng S, Lopes RD, et al. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2017. PMID: 28355434. doi:10.1001/jamacardio.2017.0065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。